Animal Model Market Report Scope & Overview:

The Animal Model Market size is estimated at USD 2.69 billion in 2025 and is expected to reach USD 5.06 billion by 2033, growing at a CAGR of 8.20% over the forecast period of 2026-2033. 

The global animal model market trend is the growing demand for preclinical testing, drug development, and biomedical research. This growth is driven by chronic diseases, cancer, and infectious diseases are becoming more common. The market is growing as more money is going into research in biotechnology and pharmaceuticals, and genetic engineering and personalized medicine are making progress. As researchers look for reliable and reproducible animal models for translational research, the market will grow in both the academic and commercial research sectors, both in the U.S. and globally. This is driven by the stricter rules for drug safety testing and the growth of contract research organizations.

For instance, in March 2024, growing demand for oncology research drove a 17% increase in rodent model procurement across North American contract research organizations, boosting preclinical testing and translational medicine adoption.

 Animal Model Market Size and Forecast:

• Market Size in 2025E: USD 2.69 billion

• Market Size by 2033: USD 5.06 billion

• CAGR: 8.20% from 2026 to 2033

• Base Year: 2025

• Forecast Period: 2026–2033

• Historical Data: 2022–2024

To Get More Information On Animal Model Market - Request Free Sample Report

Animal Model Market Report Highlights:

• Rising cancer, immune, and infectious diseases are boosting demand for validated animal models in drug development.

• Advances in genetically modified, humanized, and disease-specific models are improving research accuracy.

• CRISPR-Cas9, transgenic models, and advanced imaging are enhancing reproducibility and translational relevance.

• Digital platforms, data analytics, and AI tools enable real-time monitoring and optimized research protocols.

• Growing use of mice, rat, and custom strains supports disease modeling, toxicology, and pharmacokinetic studies.

• Industry–academia–CRO partnerships are accelerating drug discovery and clinical success.

• Regulatory bodies promote animal welfare, ethical standards, quality assurance, and alternative testing innovation.

The U.S. Animal Model Market is estimated at USD 0.85 billion in 2025 and is expected to reach USD 1.58 billion by 2033, growing at a CAGR of 8.05% over 2026-2033.

The U.S. has the biggest market share as it comprises of large pharmaceutical and biotechnology businesses, increasing investment from the government for biomedical research, and a lot of modern research infrastructure. Leading academic research centers, a lot of use of genetically altered models, and more money spent on research in oncology and immunology are all helping the market grow.

Animal Model Market Growth Drivers:

• Innovation in Genetic Engineering is Driving the Animal Model Market Growth

Innovative genetic engineering technologies are the main reason for the expansion of the animal model market. These technologies include CRISPR-Cas9 gene editing, transgenic models, and humanized animal systems, which make research more accurate and useful for real-world applications. These solutions for modeling complicated diseases and researching tailored treatment are driving the market's base, the penetration of the pharmaceutical and academic research sectors, and the overall market share globally

For instance, in June 2025, genetically engineered and humanized mouse models accounted for ~22% of the total U.S. animal model sales, reflecting growing research preference and expanding market share in precision medicine studies.

Animal Model Market Restraints:

• Ethical Concerns and Regulatory Constraints are Hampering the Animal Model Market Growth

Ethical concerns and regulatory constraints restrict the animal model market growth, as increasing public awareness about animal welfare, stringent approval processes, and the push for alternative testing methods create challenges for researchers and organizations. This might lead to delayed research timelines, increased compliance costs, and reduced accessibility to certain animal models. As a result, research outcomes may be impacted, and market growth is stunted in regions where animal welfare regulations are stringent and alternative methods are being prioritized.

Animal Model Market Opportunities:

• Expansion of Personalized Medicine Research Drive Future Growth Opportunities for the Animal Model Market

The opportunity in the expansion of personalized medicine research in animal model market is in the form of patient-derived xenografts, genetically customized models, and precision oncology platforms. These tools enable enhanced drug efficacy testing, personalized treatment tactics, and translational research capabilities. These technologies may improve the success rates of drug development, speed up the time it takes for drugs to reach the market, and grow the market by making predictions more accurate, improving clinical trial outcomes, and focusing on therapeutic development, especially in cancer and rare illness research.

For instance, in March 2024, the NIH reported that 68% of preclinical studies in oncology utilized genetically modified mouse models, highlighting rising adoption and increasing demand for specialized animal models in translational research.

Animal Model Market Segment Analysis:

• By animal type, mice held the largest share of around 46.82% in 2025E, and is expected to register the highest growth with a CAGR of 8.35%.

• By application, the cancer segment dominated the market with 42.16% share in 2025E, while the immunological disease is expected to register the highest growth with a CAGR of 8.48%.

• By end-use, pharmaceutical & biotechnology companies accounted for 48.73% share in 2025E, while the contract research organization segment is forecasted to grow the fastest at a CAGR of 8.62%.

By Animal Type, Mice Lead the Market and Register Fastest Growth

The mice segment held the largest revenue share of about 46.82% in 2025 owing to their genetic similarity to humans, rapid breeding, ease of genetic modification, and long-standing research use. Growing adoption of transgenic and knockout mouse models further strengthens this position. Additionally, the segment is expected to register the highest CAGR of nearly 8.35% from 2026 to 2033, driven by rising demand for CRISPR-based models, humanized mice, and patient-derived xenografts, alongside increased investment in precision medicine and cancer research.

By Application, the Cancer Segment Dominates, while the Immunological Disease Segment Shows Rapid Growth

The cancer segment dominated with about 42.16% revenue share in 2025, driven by high cancer prevalence, strong research funding, and the need for extensive preclinical oncology testing. Increased pharma investments, wider use of patient-derived xenograft models, and complex cancer biology further support this dominance.

The immunological disease segment is expected to register the fastest CAGR of 8.48% during 2026–2033 due to the rising autoimmune disorders, growing immunotherapy research, and focus on inflammatory diseases. Advances in immune pathway research, humanized models, and biologic therapies are key growth drivers.

By End-use, Pharmaceutical & Biotechnology Companies Lead, While Contract Research Organizations Register Fastest Growth

The pharmaceutical & biotechnology companies segment held the largest share of the animal model market at about 48.73%, driven by extensive drug pipelines, high R&D spending, and mandatory preclinical safety testing. Demand is fueled by the need for pharmacokinetic and toxicology studies, rising biologics development, and growing investment in precision medicine, requiring diverse animal models for validation, efficacy, and regulatory compliance.

In contrast, the contract research organization (CRO) segment is expected to grow at the fastest CAGR of around 8.62% during 2026–2033, as companies outsource preclinical research to cut costs and speed development. Growth is supported by strategic partnerships, specialized expertise, scalable operations, and comprehensive services such as custom model development and full study management.

Animal Model Market Regional Highlights:

Asia Pacific Animal Model Market Insights:

Asia Pacific is the fastest-growing animal model market, registering a CAGR of 9.12%, driven by expanding pharmaceutical manufacturing, rising biotech activity, and increased research infrastructure investment. Rapid economic growth, a lot of government money for life sciences, and cheap breeding facilities are all helping the industry flourish. International research partnerships and technology transfer, especially in China, India, and South Korea, are making research stronger. Also, regional growth is speeding faster because of government programs that help, lower operational costs, and more skill in genetic engineering and bespoke model development.

Get Customized Report as Per Your Business Requirement - Enquiry Now

North America Animal Model Market Insights:

North America held the largest revenue share of 41.35% in 2025 due to the strong presence of leading pharmaceutical and biotechnology companies, advanced academic research institutions, and robust government funding from agencies such as the NIH. Some of the most important factors are advanced genetic engineering, a lot of new animal models being used, strong protection of intellectual property, established breeding networks, supporting rules, and a lot of money spent on medication development in the healthcare system.

Europe Animal Model Market Insights:

The animal model market in Europe is the second-largest in the world, behind North America due to a strong pharmaceutical base, superior research infrastructure, and substantial biomedical investment in nations, such as Germany, the U.K., and France. Market expansion is nevertheless supported by the increasing usage of genetically modified models, high quality requirements, financial initiatives that help, and strong ethical review procedures.

Latin America (LATAM) and Middle East & Africa (MEA) Animal Model Market Insights:

In Latin America and the Middle East & Africa, the animal model industry is growing as the pharmaceutical industries are getting bigger, research infrastructure investments are going up, and academic institutions are getting bigger. More breeding facilities, more CROs, government life science programs, and international research partnerships all help the market grow even more.

Animal Model Market Competitive Landscape:

Charles River Laboratories International, Inc. (est. 1947) is a global leader in providing research models and preclinical services that focuses on supporting drug discovery and development globally. It uses its extensive breeding expertise and comprehensive service portfolio to produce high-quality animal models with customized research solutions.

• In January 2025, expanded its genetically engineered model repository with over 1,200 new CRISPR-edited mouse strains, enhancing research capabilities and offering improved disease modeling options for oncology and rare disease research.

The Jackson Laboratory (est. 1929) is a renowned nonprofit biomedical research institution focused on mammalian genetics and genomics. It invests in developing innovative genetically defined mouse models with the hopes of advancing understanding of human diseases through high-quality research tools and comprehensive genetic resources.

• In March 2024, launched a new humanized immune system mouse model platform for immunotherapy research, enhancing translational relevance and accelerating development of novel cancer immunotherapies across pharmaceutical partnerships.

Taconic Biosciences, Inc. (est. 1952) is a leading provider of genetically engineered rodent models and related services. The company's research model portfolio focuses on specialty models for oncology, immunology, and metabolic disease research, featuring a strong custom model development capability to complement market demands in both academic and pharmaceutical sectors.

• In November 2024, received validation approval for a new patient-derived xenograft mouse model collection targeting triple-negative breast cancer, strengthening its oncology research portfolio and expanding collaborative research opportunities with biotechnology companies.

Animal Model Market Key Players:

• Charles River Laboratories International, Inc.

• The Jackson Laboratory

• Taconic Biosciences, Inc.

• Envigo (Inotiv)

• Janvier Labs

• Crown Bioscience International

• genOway S.A.

• Harbour Antibodies BV

• Hera BioLabs

• Champions Oncology, Inc.

• Horizon Discovery Group (PerkinElmer)

• Ingenious Targeting Laboratory

• TransGenic Inc.

• PolyGene AG

• Vitalstar Biotechnology Co., Ltd.

• Shanghai Model Organisms Center, Inc.

• Beijing Vital River Laboratory Animal Technology Co., Ltd.

• GemPharmatech Co., Ltd.

• Cyagen Biosciences Inc.

• GenOway (Cegav Group)

• Ozgene Pty Ltd

• InGenious Targeting Laboratory, Inc.

• Sage Labs (now part of Horizon Discovery)